Maria E Cabanillas

Sep 9, 2024 | digitalcommons.library.tmc.edu | Sarah Hamidi |Marie-Claude Hofmann |Priyanka Iyer |Maria E Cabanillas

The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs) has undergone major advancements in the last decade, causing a paradigm shift in the management and prognosis of these patients.

May 6, 2024 | jamanetwork.com | Ali Shayanfar |Laura Boucai |Mark E. Zafereo |Maria E Cabanillas

A Review of Thyroid Cancer To the Editor A recent Review1 discussed exposure to ionizing radiation as a common risk factor for thyroid cancer. However, it is important to consider additional risk factors for thyroid cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medications used to treat type 2 diabetes, are frequently prescribed to improve glycemic control and promote weight loss.

May 6, 2024 | jamanetwork.com | Laura Boucai |Mark E. Zafereo |Maria E Cabanillas

A Review of Thyroid Cancer To the Editor A recent Review1 discussed the complexity of thyroid cancer. First, we would like to highlight the importance of distinguishing between benign and malignant thyroid nodules preoperatively.

May 6, 2024 | jamanetwork.com | Laura Boucai |Mark E. Zafereo |Maria E Cabanillas |Hormonal Disorders

A Review of Thyroid Cancer—Reply In Reply We appreciate letters about our Review on thyroid cancer.1 In response to the comments by Drs Beheshtirouy and Shayanfar, the causal association between GLP-1 RA use and thyroid cancer is complex and requires careful consideration of factors that directly or indirectly influence carcinogenesis pathways such as the direct biological effects of the drug, host susceptibility factors (eg, obesity or proinflammatory states), biases embedded in clinical...

Mar 3, 2024 | nature.com | Vivek Subbiah |Mohamed A. Gouda |Maria E Cabanillas |Behrang Amini |Funda Meric-Bernstam

AbstractPatients treated with RET protein tyrosine kinase inhibitors (TKIs) selpercatinib or pralsetinib develop RET TKI resistance by secondary RET mutations or alterative oncogenes, of which alterative oncogenes pose a greater challenge for disease management because of multiple potential mechanisms and the unclear tolerability of drug combinations. A patient with metastatic medullary thyroid carcinoma (MTC) harboring a RET activation loop D898_E901del mutation was treated with selpercatinib.